PHYSICAL-MECHANISMS OF SOLID-PROTEIN INTERACTIONS AT THE INTERFACE BETWEEN AMORPHOUS-SILICON CARBIDE AND FIBRINOGEN

被引:14
作者
BOLZ, A
SCHALDACH, M
机构
[1] Zentralinstitut für Biomedizinische Technik, Universität Erlangen-Nürnberg
来源
BIOMEDIZINISCHE TECHNIK | 1992年 / 37卷 / 11期
关键词
HEMOCOMPATIBILITY; BLOOD CLOTTING; FIBRINOGEN; AMORPHOUS SILICON CARBIDE (A-SIC-H); PECVD;
D O I
10.1515/bmte.1992.37.11.244
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
State of the art in biomaterial research and implant design is a compromise between functionality and biocompatibility. Consequently the results often have disadvantages with respect to both aspects. In regard to biocompatibility the activation of the clotting system by alloplastic materials is of great significance, because it necessitates anticoagulant therapy. Further improvements of implant technology require an understanding of the interactions between blood and implants. Therefore a microscopic model of thrombogenesis at alloplastic surfaces will shortly be presented, which relates thrombogenicity of a material to the electronic structure of its surface. The requirements for high hemocompatibility, which result from this model-especially in regard to the density of states and the conductivity at the surface-are fulfilled by an amorphous alloy of silicon and carbon (a-SiC:H). The advantage of amorphous materials is that they do not obey stoichiometric rules. Thus they allow a continous adjustment of the electronic parameters without fundamental changes of their mechanical and chemical properties. The theoretical results where checked by total internal reflection intrinsic fluorescence spectroscopy (TIRIF) as well as thrombelastography experiments (TEG). In comparison to conventional materials like titanium or LTI carbon the TEG-clotting time of a-SiC:H-coatings is prolonged in excess of 200 %. As a consequence a-SiC:H is well suited as a hemocompatible coating material for hybrid structuring of cardiovascular implants.
引用
收藏
页码:244 / 253
页数:10
相关论文
共 22 条
[1]  
AUGHTUN M, 1988, Z ZAHNARZTL IMPLANTO, V4, P228
[2]  
BAKSHI AK, 1986, CHEM PHYS, V108, P233
[3]  
BAUERSCHMIDT P, 1977, J BIOENG, V1, P261
[4]  
Bolz A, 1990, Biomed Tech (Berl), V35 Suppl 3, P21
[5]  
BOLZ A, 1991, THESIS F ALEXANDER U
[6]  
BONE S, 1981, INT J QUANTUM CHEM Q, V8, P307
[7]  
COHEN JD, 1984, SEMICONDUCTORS SEM C, V21
[8]  
DAWYDOW AS, 1977, J THEOR BIOL, V66, P379
[9]  
DOOLITTLE RF, 1981, FIBRINOGEN FIBRIN, V244, P92
[10]   SOLITON - ASSISTED ACTIVATION PROCESSES [J].
EBELING, W ;
JENSSEN, M .
BERICHTE DER BUNSEN-GESELLSCHAFT-PHYSICAL CHEMISTRY CHEMICAL PHYSICS, 1991, 95 (03) :356-362